PAI-1 Test

PAI-1 (plasminogen activator inhibitor-1) is a small protein that slams the brakes on your body's clot-dissolving system. When this brake is pressed too hard, clots stick around longer than they should, which ties directly to your risk of heart attack, stroke, and serious complications from diabetes and obesity.

The reason to care about this number is not because it diagnoses a disease on its own. It is because a high level quietly links the way your body stores fat, handles blood sugar, and responds to inflammation to the health of your blood vessels. It is one of the few blood tests that sits at the intersection of metabolic health and clotting risk.

What This Protein Actually Does

Your body is constantly making tiny clots and then breaking them down. The breakdown process is called fibrinolysis, and it depends on an enzyme called tissue plasminogen activator (tPA), which activates plasmin, the enzyme that actually cuts clots apart. PAI-1 is the main off-switch for tPA. When PAI-1 is high, tPA gets shut down, clots linger, and your blood tilts toward a pro-clotting state.

PAI-1 is made in many places, including fat cells (especially visceral fat around your organs), the cells lining your blood vessels, your liver, and platelets. That wide production explains why the number rises in obesity, inflammation, and insulin resistance. It is not just a clotting protein. It is a messenger between your metabolism and your blood vessels.

Heart Disease Risk

The clearest human evidence links higher PAI-1 to cardiovascular disease. A Framingham Heart Study analysis of 3,203 adults without prior cardiovascular disease found that people in the top quartile of PAI-1 had a 2.6-fold higher risk of a first cardiovascular event (heart attack, stroke, heart failure, or angina) over about 10 years of follow-up compared to the lowest quartile, after adjusting for conventional risk factors like blood pressure, cholesterol, and BMI.

A meta-analysis of observational studies found that people in the highest quantile of PAI-1 had about 2.17 times the odds of coronary heart disease (OR 2.17) in age- and sex-adjusted models, dropping to 1.46 times the odds after adjusting for metabolic factors. A Mendelian randomization analysis suggested the relationship may be causal, not just a bystander effect, with an odds ratio of 1.22 for coronary heart disease per unit increase in log-transformed PAI-1.

The Stockholm Heart Epidemiology Program, which looked at over 1,200 first-time heart attack cases, found that men with PAI-1 above the 90th percentile had about 1.9 times the risk after adjustment. The effect was amplified in smokers. The Caerphilly Study in 2,398 middle-aged men found a modest but independent association (about a 24% higher risk of cardiovascular events per unit increase), though the strength of the association varied depending on which risk factors were adjusted for.

Metabolic Syndrome, Obesity, and Diabetes

PAI-1 is consistently elevated in people with visceral obesity, insulin resistance, and type 2 diabetes. Fat tissue, especially the fat around your abdominal organs, is a major source of PAI-1. That is why losing visceral fat lowers the number and gaining it raises the number. The link is strong enough that some researchers consider PAI-1 a component of metabolic syndrome itself.

In healthy young adults from the Cardiovascular Risk in Young Finns Study, PAI-1 tracked with waist circumference, triglycerides, blood pressure, and glucose. The practical takeaway is that if you are carrying extra weight around the middle, or if your fasting insulin is creeping up, your PAI-1 is likely elevated too, even if your standard lipid panel still looks fine.

Cancer Associations

Higher PAI-1 is associated with worse cancer outcomes in several large cohorts. The EPICOR study followed 850 adults and found that people in the highest quartile of PAI-1 had 2.28 times the risk of developing colorectal cancer compared to the lowest quartile over a mean of 9.1 years. In breast cancer, elevated tumor tissue PAI-1 has repeatedly predicted worse survival. A 2025 prospective validation study in 813 early breast cancer patients found that high tumor uPA/PAI-1 was associated with about 2.6 times the risk of recurrence over 5 years after adjustment for tumor size, nodal status, grade, hormone receptors, and HER2 status.

These cancer findings come from tumor tissue measurements in the breast cancer studies and from blood measurements in the colorectal study. The blood test you would order directly mirrors the EPICOR finding. It is not a cancer screening test, but elevated PAI-1 sits in the broader context of inflammation and metabolic dysfunction that accompanies cancer risk.

Severe Infection and COVID-19

In severe illness, PAI-1 jumps dramatically and predicts who does badly. A meta-analysis of 4,467 sepsis patients across 18 studies found that people with elevated PAI-1 had about 3.93 times the odds of dying (OR 3.93). In COVID-19, elevated PAI-1 tracked with the development of acute respiratory distress syndrome and the need for ventilator support. This is useful context for interpreting your own number: if you had a serious infection in the weeks before your blood draw, your PAI-1 can stay elevated for some time as a leftover echo of that illness.

Reference Ranges

There are no universally standardized clinical cutpoints for PAI-1. Ranges vary considerably between labs because the protein exists in several forms (active, inactive, and bound to tPA), different assays measure different fractions, and PAI-1 loses activity quickly in the sample tube. Treat any single cutpoint as a rough guide, not a bright line.

The most important confounder to know before reading a number is the time of day the blood was drawn. Morning levels can be roughly twice afternoon levels in the same person. Ranges below come from research studies in healthy adults.

These tiers are drawn from published research, including the Framingham Heart Study (mean of 29.1 ng/mL in those who later developed cardiovascular disease versus 22.1 ng/mL in those who did not) and early standardized assay studies showing healthy adult averages around 18 ng/mL. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend.

Men typically run higher than pre-menopausal women. Levels tend to rise with age in healthy populations. Black adults tend to run lower than white adults, who tend to run lower than Hispanic adults, based on the Insulin Resistance Atherosclerosis Study.

Why One Reading Is Not Enough

PAI-1 is one of the more variable blood tests you can order. The within-person coefficient of variation is around 20 to 30%, meaning the same person can get a result 20 to 30% different on two separate draws even without any change in underlying biology. Among healthy people, between-person differences explain only about 72% of the variation in repeated measurements, with the rest coming from within-person swings and assay noise.

Serial testing beats single readings for two reasons. First, the circadian swing and biological noise mean one number can mislead you. Second, rising PAI-1 over time carries its own signal. In the Framingham Heart Study, people whose PAI-1 rose the most between baseline and a four-year follow-up had higher cardiovascular risk, independent of their starting number. Watching the slope is more informative than watching a single point.

A reasonable cadence is to get a baseline, retest in 3 to 6 months if you are making meaningful changes to weight, diet, exercise, or medications that affect PAI-1, and then at least annually. Always draw at a similar time of day and under similar conditions to make the numbers comparable.

When Results Can Be Misleading

A single PAI-1 reading can be thrown off by several things that have nothing to do with your long-term risk.

• Time of day: PAI-1 peaks in the early morning (around 6:30 AM) and can be about twice as high as afternoon values in the same person. Some people swing up to 10-fold across the day. Always draw at a consistent time.
• Recent acute illness or infection: PAI-1 is an acute phase reactant. Inflammation can push it up 2 to 4 times baseline within hours, and levels can stay elevated for a week or more after recovery. If you have had a fever, COVID, or flu in the past two to three weeks, wait before testing.
• Recent surgery or serious injury: post-operative PAI-1 rises within an hour and stays elevated for at least a week. Wait several weeks after any major surgery or trauma to get a representative number.
• Sample handling: active PAI-1 loses about half its activity after 6 hours at room temperature, so labs that handle samples slowly or inconsistently can produce artificially low results.

Dietary shifts in the few days before a draw can also move the number. A short run of high-fat eating can raise PAI-1 within about a week; a diet rich in monounsaturated fats or fiber tends to lower it. If you want a stable baseline, keep your eating pattern consistent for at least a week before the blood draw.

A Note on What the Blood Test Misses

Roughly 90% of the total PAI-1 in your blood is stored inside platelets, not floating free in plasma. The standard blood test measures the plasma pool, not the platelet pool. When a clot actually forms, platelets dump their PAI-1 locally, and that burst is not captured in your lab number. This is one reason PAI-1 is better thought of as a risk marker tied to metabolic health than as a direct measure of how well you will dissolve a specific clot.